|
Volumn 26, Issue 6, 2012, Pages
|
Integrating innovative therapeutic strategies into the management of renal cell carcinoma
a,b,c a,b,c,d a,b,c,d |
Author keywords
[No Author keywords available]
|
Indexed keywords
ALPHA INTERFERON;
AXITINIB;
BEVACIZUMAB;
CARBOPLATIN;
CISPLATIN;
DOXORUBICIN;
EVEROLIMUS;
GEMCITABINE;
HYPOXIA INDUCIBLE FACTOR;
INTERFERON;
INTERLEUKIN 2;
IPILIMUMAB;
MAMMALIAN TARGET OF RAPAMYCIN;
PAZOPANIB;
RECOMBINANT ALPHA2A INTERFERON;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
VASCULOTROPIN;
ANTINEOPLASTIC ACTIVITY;
BLEEDING;
CANCER COMBINATION CHEMOTHERAPY;
CANCER CONTROL;
CANCER IMMUNOTHERAPY;
CANCER RADIOTHERAPY;
CANCER SIZE;
CANCER SURVIVAL;
CARCINOGENESIS;
COMPARATIVE EFFECTIVENESS;
CRYOABLATION;
DRUG EFFICACY;
FEVER;
FLU LIKE SYNDROME;
HIGH INTENSITY FOCUSED ULTRASOUND;
HUMAN;
KIDNEY CARCINOMA;
KIDNEY METASTASIS;
LAPAROSCOPIC SURGERY;
METASTASIS;
MOLECULARLY TARGETED THERAPY;
MONOTHERAPY;
MULTIMODALITY CANCER THERAPY;
NEPHRECTOMY;
NONHUMAN;
PROGRESSION FREE SURVIVAL;
RADIATION DOSE;
RADIOFREQUENCY ABLATION;
RECURRENCE FREE SURVIVAL;
REVIEW;
STEREOTACTIC BODY RADIATION THERAPY;
STEREOTACTIC RADIOSURGERY;
STRATEGIC PLANNING;
TUMOR VASCULARIZATION;
URETER INJURY;
URETER STRICTURE;
|
EID: 84874797798
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (12)
|
References (0)
|